Rapid Micro Biosystems Posts $0.23 Per-Share Loss as Merck Offers $0.75 Per Share in Cash
Key Facts
Rapid Micro Biosystems posted a net loss of $11.3 million, or $0.23 per share, in the third quarter of 2026, according to a company statement accompanying its filing with the U.S. Securities and Exchange Commission. The loss narrowed from $11.5 million, or $0.26 per share, in the third quarter of 2025. On November 16, the company announced a definitive agreement under which Merck KGaA will acquire all of its outstanding shares for $0.75 per share in cash. The deal is expected to close in December 2026, subject to the satisfaction of conditions and completion of the tender offer. The results come as the deal ties the company’s future and its Growth Direct platform to Merck’s life sciences business.
Growth in product and services revenue boosted overall activity during the quarter. Product revenue rose 24.9% to $6.5 million, compared with $5.2 million in the same period of 2025, according to the company statement. Services revenue increased 14.9% to $3.0 million from $2.6 million. Recurring revenue also rose 6.9% to $5.2 million, versus $4.8 million a year earlier. The figures show year-over-year improvement across all three revenue components, while the net loss remained $11.3 million for the quarter.
Gross margin reached a quarterly record of 25.2%, equivalent to $2.4 million, compared with a margin of 8.9% and gross profit of $0.7 million in the third quarter of 2025, the company said. Adjusted EBITDA loss, a non-GAAP measure, also improved to $7.9 million from $9.4 million a year earlier. Operating expenses, however, rose 8.1% to $13.0 million, compared with $12.1 million in the year-earlier quarter. Total expenses included a one-time restructuring charge of $0.7 million. The company said the charge was related to the efficiency program it announced in August 2026, while the comparison shows improved margin and a narrower adjusted EBITDA loss alongside continued growth in operating expenses.
On commercial execution, the company placed 7 new Growth Direct systems and completed validation of 12 customer systems in the third quarter of 2026. In the same period of 2025, it placed 5 systems and completed 4 validations, according to the statement. The chief executive said the partnership with Merck over the previous eighteen months had focused on innovation and helping customers modernize quality-control procedures. He added that the company expects joining Merck’s life sciences business to expand the reach of the Growth Direct platform. The increase in placements and validations combines indicators of current commercial activity with the company’s plan tied to the announced deal.
Cash, cash equivalents and short-term investments totaled about $7 million as of September 30, 2026, according to the company statement. The annual performance context dates to its report on the third quarter of 2025, when it reported quarterly revenue of $7.8 million, up 3% from the third quarter of 2024. The company then raised the lower end of its 2025 revenue guidance to $33 million. In the current results announcement, it withdrew its full-year 2026 guidance following the acquisition announcement and said it would not hold a conference call to discuss the quarter’s results. Full-year guidance that had been in place is therefore no longer the focus of the current filing, as investors turn their attention to the deal terms and closing process.
The company also announced that it would delay filing its quarterly report, Form 10-Q, for the quarter ended September 30, 2026, and intends to file it within the extension period permitted under Rule 12b-25, according to its filing. This makes the report filing one of the next announced steps following the results, alongside completion of the tender offer. The Merck deal remains subject to the satisfaction of its requirements, although the company expects it to close in December 2026. The agreement sets cash consideration of $0.75 per share for all outstanding shares. The company also withdrew its 2026 guidance and will not hold an earnings conference call, according to its announcement.